PRESS RELEASES
Regenetech receives "Most Promising Life Science Technology Company" Award at a regional Venture Forum
18 June 2007
Regenetech Inc., the adult stem cell company which uses NASA-licensed technology, garnered top honors as a “Most Promising Life Science Technology Company” at the 6th Annual Life Science Technology Venture Forum.
At the event, the top ten most promising life science technology companies were selected from more than 30 emerging life science companies who showcased their new ventures to an audience of over 425 attendees, including: investors; venture capitalists; industry representatives; business leaders; advisors/mentors; service providers; and entrepreneurs. The winners were chosen based on the companies' 'elevator pitch' presentations and were selected by a judging panel made up of investors and business leaders.
Regenetech was also one of five companies chosen to present its business plan during the day-long event. Under license from NASA, Regenetech has extended NASA’s patented human progenitor cell technology for use in stem cell expansion based on peripheral or umbilical cord blood sources of stem cells and orthopedics. The company has filed nearly 200 patent applications globally.
The program was hosted by the Rice Alliance and co-hosted by the UT MD Anderson Cancer Center and held at Jesse H. Jones Graduate School of Management at Rice University. Panelists included eight leading venture capitalists and investors, and the keynote speakers were B.J. Bormann, Ph.D., Vice President of Pfizer Global R&D; John Mendelsohn, M.D., President, UT M.D. Anderson Cancer Center; and Nancy Chang, Ph.D., Co-founder and Chairman, Tanox, Inc.
David Bonner, CEO of Regenetech, said: “We are delighted to receive this accolade from our peers within the life science technology field, which highlights increasing interest in Regenetech’s novel technology from well respected investors and business leaders. The Life Science Technology Venture Forum is a great opportunity to showcase companies and their technology, and Regenetech is pleased to have received such recognition from such a specialist audience.”
For further information:
Regenetech, Inc. |
|
Dr. David Bonner, Chief Executive Officer |
Tel: 00 1 713 212 0671 |
Media enquiries:
Abchurch |
|
Franziska Böhnke / Joanne Shears |
Tel: +44 (0) 20 7398 7709 |
Notes to Editors:
Regenetech is a leading adult stem cell company that uses NASA licensed technology to expand adult stem cells in a simulated weightless three-dimensional environment. The stem cells are taken from the patient’s peripheral blood, and Regenetech’s IntrifugeTM Bioreactor filters and expands therapeutic qualities before re-introducing them back into the original patient The Bioreactor maintains cell-to-cell geometry and communication throughout the expansion process with no differentiation or cell death. The Company’s technologies provide the opportunity to treat serious diseases such as diabetes, heart disease and stroke; there are at least 300 million people in the US, EU and Japan who could potentially benefit from stem cell therapeutics now in development.
Regenetech has a series of agreements with prestigious universities in order to further refine its technologies and to develop potential treatments for diabetes and bone/cartilage repair. In addition, its technology is being used in trials in the field of veterinary orthopaedics, whereby the IntrifugeTM Bioreactor’s magnetic fields assist in the repair of broken bones in animals.
The Company has a dual track revenue strategy in order to maintain a balance between short and medium term earnings. The Company licenses out technologies for treatments, as well as progressing therapies through the usual biologics clinical trials cycle, which is significantly shorter and less costly than the conventional drugs’ clinical trials process.
About the Rice Alliance for Technology and Entrepreneurship
The Rice Alliance for Technology and Entrepreneurship (Rice Alliance) is Rice University's flagship initiative devoted to the support of technology entrepreneurship. The Rice Alliance is a collaboration among the Brown School of Engineering, the Jones Graduate School of Management, and the Wiess School of Natural Science.
Since its inception in late-1999, the Rice Alliance has assisted in the launch of over 205 new technology companies, which have raised more than $300 million in early stage funding. The mission of the Rice Alliance is to conduct research and support the creation of technology-based companies and the commercialization of new technologies. The Rice Alliance provides entrepreneurs with a collaborative network and forum for support, education, and exchange of ideas. It offers entrepreneurs access to the human and financial capital needed for success.